Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Another key plank of Amgen’s remarkable growth in the 1990s and early 2000s was through mergers and acquisitions. It focused on other innovative biotechnology companies, acquiring Synergen in ...

Dogs of the Dow stocks are not only higher on the year but still offer big yields and a degree of safety from tariffs.

Globe Magazine profile of the reclusive investor and philanthropist who’d quietly bought up half of Harvard Square.

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Amgen has reported positive phase 3 results ... Complement C5 inhibitor Soliris is the flagship product in AZ's $39 billion acquisition of Alexion, which closed last year, making $2 billion ...